The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Chia Tai Tianqing Pharmaceutical Group (Inst)
Safety and efficacy of TQ-B3525, a novel and selective oral PI3K α/δ inhibitor, in Chinese patients with advanced malignancies: A phase I dose-escalation and expansion trial.
 
Huaqing Wang
Research Funding - Chia Tai Tianqing Pharmaceutical Group (Inst)
 
Wenqi Jiang
Research Funding - Chia Tai Tianqing Pharmaceutical Group (Inst)
 
Su Li
Research Funding - Chia Tai Tianqing Pharmaceutical Group (Inst)
 
Yu Wang
Research Funding - Chia Tai Tianqing Pharmaceutical Group (Inst)
 
Peng Sun
Research Funding - Chia Tai Tianqing Pharmaceutical Group (Inst)
 
Pei Zhou
Research Funding - Chia Tai Tianqing Pharmaceutical Group (Inst)
 
Yang Zheng
Research Funding - Chia Tai Tianqing Pharmaceutical Group (Inst)
 
Jing Zhan
Research Funding - Chia Tai Tianqing Pharmaceutical Group (Inst)
 
Zhiming Li
No Relationships to Disclose